Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6968808 | 0.98 | SIGMAR1 (0.45) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL6963725 | 0.94 | SIGMAR1 (0.57) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL6971465 | 0.91 | SIGMAR1 (0.53) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL6967497 | 0.89 | — | — | |
| SCHEMBL4468595 | 0.86 | SIGMAR1 (0.42) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL6973979 | 0.85 | SIGMAR1 (0.47) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL4465067 | 0.84 | SIGMAR1 (0.39) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL11655160 | 0.84 | SIGMAR1 (0.52) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL6975542 | 0.83 | SIGMAR1 (0.44) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL6968173 | 0.82 | SIGMAR1 (0.42) | SIGMAR1CYP1A2KDM5APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-0870765-B1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARM CO LTD (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | SIGMAR1 129/4885CYP1A2 720/4885KDM1A 1203/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | SIGMAR1 129/4885CYP1A2 720/4885KDM1A 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.